de Vicente et al. [38] revealed that the SOX2 expression was an important predictive biomarker of oral cancer risk in early stage patients, while Zhan et al. [39] identified that the aberrant expression of SOX2 can inhibit esophageal squamous cell carcinoma development. Here, SOX2 is linked to esophageal squamous cell carcinoma.